Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL23R | Q5VWK5 | 9/20 | 0.57 |
| ▸ | TFPI | P10646 | 1/20 | 0.56 |
| ▸ | VIPR2 | P41587 | 5/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.54 |
| ▸ | NPY1R | P25929 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 2/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509135 | 1.00 | IL23R (0.57) | IL23RTFPIVIPR2VIPR1NPY1R | |
| SCHEMBL16509090 | 0.96 | TFPI (0.60) | IL23RTFPIVIPR2VIPR1 | |
| SCHEMBL16509000 | 0.94 | TFPI (0.59) | IL23RTFPIVIPR2VIPR1 | |
| SCHEMBL29353517 | 0.92 | TFPI (0.57) | IL23RTFPINPY1RNPY4RNPY5R | |
| SCHEMBL16509040 | 0.88 | NPY4R (0.58) | IL23RTFPINPY1RNPY4RNPY5R | |
| SCHEMBL8894047 | 0.87 | VIPR2 (0.52) | IL23RVIPR2VIPR1 | |
| SCHEMBL30782799 | 0.86 | VIPR2 (0.54) | IL23RVIPR2VIPR1NPY1RNPY4R | |
| SCHEMBL29973963 | 0.85 | F2 (0.52) | IL23RTFPI | |
| SCHEMBL29974829 | 0.85 | F2 (0.52) | IL23RTFPI | |
| SCHEMBL29479830 | 0.85 | VIPR1 (0.69) | TFPIVIPR2VIPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | IL23R 677/4885TFPI 1325/4885VIPR2 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.